Savara Pharmaceuticals

Savara is developing innovative pulmonary drugs to address serious and life-threatening conditions. Our lead product is AeroVanc (vancomycin hydrochloride inhalation powder), is an inhaled dry powder form of vancomycin in a capsule-based inhaler intended to treat MRSA infections in patients with cystic fibrosis or other lung-compromising conditions. Savara is led by an experienced team of proven entrepreneurs and life science professionals with decades of inhalation product development experience.


Date Type Amount Investors Valuation
06/01/12 Series B 8.6M The Keiretsu Forum Unknown